DNA拓扑异构酶及其被抗癌和抗菌药物抑制的情况。
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
作者信息
Pommier Yves, Leo Elisabetta, Zhang HongLiang, Marchand Christophe
机构信息
Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4255, USA.
出版信息
Chem Biol. 2010 May 28;17(5):421-33. doi: 10.1016/j.chembiol.2010.04.012.
Abstract
DNA topoisomerases are the targets of important anticancer and antibacterial drugs. Camptothecins and novel noncamptothecins in clinical development (indenoisoquinolines and ARC-111) target eukaryotic type IB topoisomerases (Top1), whereas human type IIA topoisomerases (Top2alpha and Top2beta) are the targets of the widely used anticancer agents etoposide, anthracyclines (doxorubicin, daunorubicin), and mitoxantrone. Bacterial type II topoisomerases (gyrase and Topo IV) are the targets of quinolones and aminocoumarin antibiotics. This review focuses on the molecular and biochemical characteristics of topoisomerases and their inhibitors. We also discuss the common mechanism of action of topoisomerase poisons by interfacial inhibition and trapping of topoisomerase cleavage complexes.
摘要
DNA拓扑异构酶是重要的抗癌和抗菌药物的作用靶点。喜树碱以及正在临床开发中的新型非喜树碱类药物（茚并异喹啉和ARC - 111）作用于真核生物IB型拓扑异构酶（Top1），而人类IIA型拓扑异构酶（Top2α和Top2β）是广泛使用的抗癌药物依托泊苷、蒽环类药物（多柔比星、柔红霉素）和米托蒽醌的作用靶点。细菌II型拓扑异构酶（回旋酶和拓扑异构酶IV）是喹诺酮类和氨基香豆素类抗生素的作用靶点。本综述重点关注拓扑异构酶及其抑制剂的分子和生化特性。我们还讨论了拓扑异构酶毒物通过界面抑制和捕获拓扑异构酶切割复合物的共同作用机制。
相似文献
1
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.DNA拓扑异构酶及其被抗癌和抗菌药物抑制的情况。
Chem Biol. 2010 May 28;17(5):421-33. doi: 10.1016/j.chembiol.2010.04.012.
2
Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.嵌入型 TOP2 毒物在较高浓度时会减弱拓扑异构酶的作用。
Mol Pharmacol. 2019 Oct;96(4):475-484. doi: 10.1124/mol.119.117259. Epub 2019 Aug 9.
3
[Screening of DNA topoisomerase inhibitors].[DNA拓扑异构酶抑制剂的筛选]
Gan To Kagaku Ryoho. 2004 Apr;31(4):495-500.
4
DNA Topoisomerases as Targets for Antibacterial Agents.作为抗菌剂靶点的DNA拓扑异构酶
Methods Mol Biol. 2018;1703:47-62. doi: 10.1007/978-1-4939-7459-7_3.
5
Topoisomerases as anticancer targets.拓扑异构酶作为抗癌靶点。
Biochem J. 2018 Jan 23;475(2):373-398. doi: 10.1042/BCJ20160583.
6
Targeting bacterial topoisomerases: how to counter mechanisms of resistance.靶向细菌拓扑异构酶：如何克服耐药机制。
Future Med Chem. 2016 Jun;8(10):1085-100. doi: 10.4155/fmc-2016-0042. Epub 2016 Jun 10.
7
DNA topoisomerases as molecular targets for anticancer drugs.DNA 拓扑异构酶作为抗癌药物的分子靶点。
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1781-1799. doi: 10.1080/14756366.2020.1821676.
8
Mechanisms of resistance to drugs that inhibit DNA topoisomerases.对抑制DNA拓扑异构酶药物的耐药机制。
Semin Cancer Biol. 1991 Aug;2(4):235-44.
9
Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity.拓扑异构酶与蒽环类药物：抗癌治疗及心脏毒性预防的最新进展与展望
Curr Med Chem. 2017;24(15):1607-1626. doi: 10.2174/0929867323666161214120355.
10
Drugging topoisomerases: lessons and challenges.靶向拓扑异构酶药物：经验与挑战。
ACS Chem Biol. 2013 Jan 18;8(1):82-95. doi: 10.1021/cb300648v. Epub 2013 Jan 4.
引用本文的文献
1
The Efficacy of Doxorubicin in Capsule Contracture Associated with Silicone Implants.阿霉素治疗硅胶植入物相关包膜挛缩的疗效
Aesthetic Plast Surg. 2025 Sep 2. doi: 10.1007/s00266-025-05166-3.
2
Exploring the anticancer and antioxidant properties of Lagerstroemia speciosa bark extract via phytochemical and molecular docking analysis.通过植物化学和分子对接分析探索紫薇树皮提取物的抗癌和抗氧化特性。
J Genet Eng Biotechnol. 2025 Sep;23(3):100553. doi: 10.1016/j.jgeb.2025.100553. Epub 2025 Aug 14.
3
Metabolic Culture Medium Enhances Maturation of Human iPSC-Derived Cardiomyocytes via Cardiac Troponin I Isoform Induction.代谢培养基通过诱导心肌肌钙蛋白I亚型增强人诱导多能干细胞衍生心肌细胞的成熟。
Int J Mol Sci. 2025 Jul 26;26(15):7248. doi: 10.3390/ijms26157248.
4
Advances in Doxorubicin Chemotherapy: Emerging Polymeric Nanocarriers for Drug Loading and Delivery.阿霉素化疗的进展：用于药物负载和递送的新型聚合物纳米载体
Cancers (Basel). 2025 Jul 10;17(14):2303. doi: 10.3390/cancers17142303.
5
Dynamic crosstalk between amino acid metabolism and cancer drug efficacy: From mechanisms to therapeutic opportunities.氨基酸代谢与癌症药物疗效之间的动态相互作用：从机制到治疗机遇
iScience. 2025 Apr 11;28(5):112405. doi: 10.1016/j.isci.2025.112405. eCollection 2025 May 16.
6
Polymerase Ѳ inhibitors combinations with approved and investigational agents in patient-derived tumor multi-cell type (mct) spheroids.聚合酶Ѳ抑制剂与已批准和正在研究的药物在患者来源的肿瘤多细胞类型（mct）球体中的联合应用。
Exp Mol Pathol. 2025 Jun 27;143:104978. doi: 10.1016/j.yexmp.2025.104978.
7
Exploring Carboxamide Derivatives as Promising Anticancer Agents: Design, In Vitro Evaluation, and Mechanistic Insights.探索羧酰胺衍生物作为有前景的抗癌药物：设计、体外评估及作用机制洞察
Int J Mol Sci. 2025 Jun 19;26(12):5903. doi: 10.3390/ijms26125903.
8
Elacridar Inhibits BCRP Protein Activity in 2D and 3D Cell Culture Models of Ovarian Cancer and Re-Sensitizes Cells to Cytotoxic Drugs.艾拉司群在卵巢癌的二维和三维细胞培养模型中抑制乳腺癌耐药蛋白（BCRP）的蛋白活性，并使细胞对细胞毒性药物重新敏感。
Int J Mol Sci. 2025 Jun 17;26(12):5800. doi: 10.3390/ijms26125800.
9
Ferroptotic- and non-ferroptotic mechanisms associated with doxorubicin-induced male reproductive dysfunction.与阿霉素诱导的雄性生殖功能障碍相关的铁死亡和非铁死亡机制。
Toxicol Rep. 2025 Jun 4;14:102064. doi: 10.1016/j.toxrep.2025.102064. eCollection 2025 Jun.
10
Hybrid thiazolyl-benzylidene-phenol metal complexes as novel chemotherapeutic agents with anti-topoisomerase I activity in human breast carcinoma: synthesis, and studies.杂合噻唑基-亚苄基-苯酚金属配合物作为具有抗人乳腺癌拓扑异构酶I活性的新型化疗药物：合成与研究
RSC Adv. 2025 Jun 17;15(26):20552-20569. doi: 10.1039/d5ra00889a. eCollection 2025 Jun 16.
本文引用的文献
1
Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription.拓扑异构酶I通过防止复制和转录之间的干扰来抑制基因组不稳定。
Nat Cell Biol. 2009 Nov;11(11):1315-24. doi: 10.1038/ncb1984. Epub 2009 Oct 18.
2
A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage.一种修复拓扑异构酶介导的DNA损伤的人类5'-酪氨酰DNA磷酸二酯酶。
Nature. 2009 Oct 1;461(7264):674-8. doi: 10.1038/nature08444.
3
Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.14-(氨烷基-氨甲基)芳香喜树碱的合成与生物评价作为拓扑异构酶 I 抑制剂：探究共享结构-活性关系的假说。
Bioorg Med Chem. 2009 Oct 15;17(20):7145-55. doi: 10.1016/j.bmc.2009.08.066. Epub 2009 Sep 6.
4
Quinolones: action and resistance updated.喹诺酮类药物：作用机制与耐药性更新。
Curr Top Med Chem. 2009;9(11):981-98. doi: 10.2174/156802609789630947.
5
Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks.蛋白酶体依赖性将拓扑异构酶I-DNA加合物加工成停滞复制叉处的DNA双链断裂。
J Biol Chem. 2009 Oct 9;284(41):28084-28092. doi: 10.1074/jbc.M109.030601. Epub 2009 Aug 6.
6
New inhibitors of bacterial topoisomerase GyrA/ParC subunits.细菌拓扑异构酶GyrA/ParC亚基的新型抑制剂。
Curr Opin Investig Drugs. 2009 Aug;10(8):804-10.
7
Cell cycle kinases as therapeutic targets for cancer.细胞周期激酶作为癌症的治疗靶点。
Nat Rev Drug Discov. 2009 Jul;8(7):547-66. doi: 10.1038/nrd2907.
8
A journey in the world of DNA rings and beyond.DNA环及其他领域的探索之旅。
Annu Rev Biochem. 2009;78:31-54. doi: 10.1146/annurev.biochem.78.030107.090101.
9
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.DNA拓扑异构酶I抑制剂：化学、生物学及界面抑制
Chem Rev. 2009 Jul;109(7):2894-902. doi: 10.1021/cr900097c.
10
Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases.对IIA型拓扑异构酶喹诺酮-DNA切割复合物的结构洞察。
Nat Struct Mol Biol. 2009 Jun;16(6):667-9. doi: 10.1038/nsmb.1604. Epub 2009 May 17.
Zotero 插件